Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 961-968

  Villa, Raffaella ^a   Gornati, Daniela ^a   Zaffaroni, Nadia ^a,b   Veneroni, Silvia ^a   Bidoli, Paolo ^a   Severini, Aldo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Ist Nazionale Studio Cura Tumori   (Italy)

Author keywords

Anticancer agents; Cytotoxicity; Human cholangiocarcinoma; Human colon adenocarcinoma; Modulators; Sulforhodamine assay

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LONIDAMINE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0030932752     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Altaee MY, Johnson PJ, Farrant JM and Williams R: Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 68: 2051-2054,1991.
2. Maxwell Parkin D, Ohshima H, Srivatanakul P and Vatanasapt V: Cholangiocarcinoma: Epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidem Biomar Prev 2: 537-544, 1993.
3. Rosen CB and Nagorney DM: Cholangiocarcinoma complicating primary sclerosing cholangitis. Semin Liver Dis 11: 26-30, 1991.
4. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Kanjanapitak A, Varavithya W, Phuapradit P, Bunyaratvej S, Upatham ES and Brockelman WY: Opisthorchis Viverini infection and cholangiocarcinoma. A prospective case control study. Gastroenter 89: 151-156, 1985.
5. Hadjis NS, Blenkharm JI, Alexander N, Benjamin IS and Blumgart LH: Outcome of radical surgery in hilur cholangiocarcinoma. Surgery 107: 597-604 1990.
6. Alexander F, Rossi RL, O'Bryan M, Khettriy V, Braasch JW and Warkins E: Biliary carcinoma: a review of 109 cases. Am J Surg 147: 503-509,1984.
7. Lotze MT, Flickinger JC and Carr BI: Cancer of the biliary system. In: "Cancer Principles and Practice of Oncology", ed. De Vita VT, Hellmann S and Rosemberg SA, pp. 900-906, 1993. Lippincott, Philadelphia.
8. Ottow RT, August DA and Sugarbaker PH: Treatment of proximal biliary tract carcinoma: an overview of techniques and results. Surgery 97: 251-262, 1985.
9. Banerjee B and Teplick SK: Non surgical management of primary cholangiocarcinoma. Digest Dis Sci 40: 70l-705, 1995.
10. Miyazaki K, Kazumitsu N and Fumio N: Bypass procedure for bile duct cancer. World J Surg 12: 64-67, 1988.
11. Yamakawa T, Esguerra RD, Hitoshi K and Fukuma E: Percutaneous therapeutic endoprosthesis in malignant obstruction of the bile duct. World J Surg 12: 78-84, 1988.
12. Salomonowitz EK, Adam A, Antonucci F, Stuckmann G and Zollikofer CL: Malignant biliary obstruction: treatment with self- expandable stainless steel endoprosthesis, Cardiovasc Inter Rad 15: 351-355, 1992.
13. Edc RJ, Williams SJ, Hatfield ARW, Mclntyre S and Mair G: Endoscopie management of inoperable cholangiocarcinoma using irridium-192. Br J Surg 76: 867-869, 1989.
14. Falkson G, Mclntyre JM and Moertal CG: Eastern cooperative oncology group experience with chemotherapy for inoperable gall bladder and bile duct cancer. Cancer 54: 965-969, 1984.
15. Gonzalez DG, Gerard JP, Manners AW, De La Lande-Guyaux B, Van Dijk-Milatz, Meerwaldt JH, Bosset JF and Van Dijk JDP: Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis 10: 131-141, 1990.
16. Fogel TD and Weissberg JB: The role of radiation therapy in carcinoma of the extrahepatic bile ducts, Int J Radial Oncol Biol Phys 10: 2251-225 8, 1984.
17. Von Eyben F, Hellekant C, Mattson M, Ljungquist V and Jonsson K: Mitomycin-C in advanced gallbladder carcinoma. Acta Radiol 19: 8184, 1980.
18. Harvey JH, Smith FP and Schein PS: 5-FluorouraciI, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2: 1245-1248, 1984.
19. Uchiyama K, Tukada T and Yasuda H: A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin, and mitomycin C chemotherapy. Gan to Kagaku Ryoho (English abstract) 15: 19871990, 1988.
20. Stillwagon GB, Order SE, Haulk T, Herpst J, Ettinger DS, Fishman EK, Klein JL and Leichner PK: Variable low dose rate irradiation (131 I-Anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 21: 1601-1605, 1991.
21. Novell JR, Dusheiko G, Markham NI and Reddy K: Selective regional chemotherapy of unrescctable hepatic tumours using lipiodol. HPB Surg 4: 223-234, 1991.
22. Wada H, Sasaki Y, Imaoka S and Shibata T: Intra-arterial and intraportal therapy combined with decollateralization in unresectable cholangiocellular carcinoma: A case report. Gan To Kagaku Ryoho 16: 2867-2870, 1989.
23. Zaffaroni N, Villa R, Daidone MG, Vaglini M, Santinami M and Silvestrini R: Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. Int J Cell Clon 7: 385-394, 1989.
24. Silvestrini R, Zaffaroni N, Villa R, Orlandi L and Costa A: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52: 813-817,1992.
25. Storto PD. Saidman SL, Demetris AJ, Letessier E, Whiteside TL and Gollin SM: Chomosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes and Cancer 2: 300-310, 1990.
26. Ferez RP, Godwin AK, Handel LM and Hamilton TC: A comparison of clonogenic microtctrazolium and sulforhodumine B assays for determination of cisplalin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 29A: 395-399, 1993.
27. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R and Silvestrini R: Expression of p-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 30A: 1002-1007, 1994.
28. Orlandi L, Zaffaroni N. Gornati D, Veneroni S and Silvestrini R: Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer. Anticancer Res 14: 1161-1164, 1994.
29. Agnantis NJ, Pc Iraki C, Markoulatos P and Spandidos DA: Immunohistochemical study of the ras oncogene expression in human breast lesions. Anticancer Res 6: 1157-1160, 1986.
30. Zaffaroni N, Benini E, Gornati D, Bearzatto A and Silvcstrini R: Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells 13: 77-85, 1995.
31. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mczzeiti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p-53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
32. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodrigues G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, LeBail N and Vonhoof D: Phase 1 clinical trial of taxotere admistered as either 2 hours or 6 hours intravenous infusion. J Clin Oncol 11: 950-958, 1993.
33. Crooke ST and Bradner WT: Mitomycin-C: a review. Cancer Treat Rev 3: 121-139, 1976.
34. Muller C, Laval F, Soues S, Birck C and Charcosset JY: High cell density-dependent resistance and p-glycoprotein-mediated multidrug resistance in mitoxantrone-selected Chinese hamster cells. Biochem Pharmacol 43: 2091-2102, 1992.
35. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelly K, Morrow C and Cowan KH: Reduced intracellular drug accumulation in the absence of p-glycoprotein (mdr-1) ovcrexpression in mitoxantroneresistant human MCF-7 breast cancer cells. Cancer Res 52: 6175-6181, 1992.
36. Ganapathi R and Grabowski D: Differential effect of the calmodulin inhibitor trifluoperazione in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin resistant L1210 mouse leukemia cells: Lack of correlation between cellular doxorubicin levels and expression of resistance. Biochem Pharmacol 37: 185-193, 1988.
37. Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D and Pommier Y: Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug- induced topoisomerase II-mediated DNA cleavage. Cancer Commun 1: 217-224, 1989.
38. Eliason JF, Ramuz H, Yoshikubo T, Ishikawa T, Yamamoto T, Tsuruo T: Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro. Biochcm Pharmacol 50: 187-196, 1995.
39. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF and Hamilton TC: Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53: 5225-5232, 1993.
40. U Isonishi S, Horn DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A and Howell SB: Expression of the c-Hras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 57: 5903-5909, 1991.
41. Nelson WG and Kastan MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
42. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M and Hamilton TC: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloro-platinum (II) in human ovarian cancer cell lines. Cancer Res 48: 5713-5716, 1988.
43. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Boltini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M. and Perroni D: A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study. Int J Oncol 4: 747-752, 1994.
44. Silvestrini R, Zaffaroni N, Villa R, Orlandi L and Costa A: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52: 813-817, 1992.
45. Besner JG, Leclaive R, Band PR, Deschamps M, De Sanctis AJ and Catanese B: Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 41: 48-52, 1984.